Ipecac’s status
This article was originally published in The Tan Sheet
Executive Summary
Recommendations by FDA's Nonprescription Drugs Advisory Committee meeting June 12 to discontinue Ipecac's OTC status "do not adequately represent the perspective of many practicing medical toxicologists," Richard Dart, MD/PhD, says in July 22 comments filed with the agency (1"The Tan Sheet" June 16, 2003, p. 3). Ipecac is useful in cases of iron and acetaminophen ingestion and for households in rural areas, the Rocky Mountain Poison Center Director argues. Therefore, Dart requests FDA wait until the tentative final monograph for OTC Poison Treatment Drug Products is "adopted before making its decision on the fate of syrup of Ipecac"...